WALTHAM, Mass., April 24, 2025 /PRNewswire/ -- Everest Biolabs, a pioneering life sciences company dedicated to elevating extracellular vesicle (EV) and exosome research, announced the launch of innovative products at the International Society for Extracellular Vesicles (ISEV2025) Annual Meeting in Vienna. These products, including the Summit instrument, advance Everest's mission to enable the use of EVs in biomarker discovery and diagnostic applications. The new Everest Biolabs products showcased at ISEV2025 include:
George Daaboul, CEO and co-founder of Everest Biolabs, emphasized, "Our new products remove bottlenecks in EV isolation and analytics by providing scientists with precise, scalable, and reliable tools. By simplifying and automating complex workflows, we're accelerating discoveries that ultimately translate into impactful clinical applications."
Tal Gilboa, co-founder and Head of Research at Everest Biolabs, will present a poster (#477) on Thursday April 24, highlighting recent data from the new products.
ISEV2025 attendees are encouraged to visit Everest Biolabs at Booth #G5 for live product demonstrations and information about early access opportunities.
About Everest Biolabs
Everest Biolabs, founded on technology from David Walt's laboratory at the Wyss Institute, is dedicated to reaching excellence in EV research through the relentless focus on high-quality, easy-to-use tools for EV isolation and analytics. Our solutions enhance workflows, from foundational EV isolation to advanced analytics, enabling groundbreaking discoveries. With a vision to unlock the potential of EVs in clinical applications, we keep 'science first' while fostering innovation and integrity in everything we do. Based near Boston, MA we're here to elevate exosome research at every step. Learn more at everestbiolabs.com.
Contact:
David Freedman
media@everestbiolabs.com
everestbiolabs.com
SOURCE Everest Biolabs, Inc.